Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Organon CEO Uncertain Over Long-Term Future Of Biosimilars Business

Kevin Ali: ‘I Don't Know Where The Biosimilar Business Will Be In The Next Decade’

Executive Summary

Organon CEO Kevin Ali has acknowledged that the long-term future for the biosimilars business is unclear, despite the firm’s biosimilars segment currently acting as a solid growth driver for the company.

You may also be interested in...



Differentiation Is Mantra As Amneal Targets $1bn By 2030 From Non-US Geographies

As Amneal makes its commercial debut in markets outside the US, Shyamakant Giri, MD and president, India and emerging markets, formulates a strategy based on differentiation and a targeted approach. From ‘theranostics’ to partnered products, he has multiple aces up his sleeves, Giri tells Scrip in an interview.

Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab

Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.

Organon Outlines Importance Of Speed For US Humira Opportunity

At its debut year-end financial earnings call, Organon spoke in further detail about the impending launch of Humira biosimilars, as well as its desire to continue growing its portfolio.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152423

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel